# A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

> **NCT03150719** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 98 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Tezacaftor/Ivacaftor
- **DRUG:** Ivacaftor
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03150719
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-24
- **Primary completion:** 2018-08-09
- **Final completion:** 2018-08-09
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150719, "A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03150719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*